Impact of ixekizumab treatment on skin‐related personal relationship difficulties in moderate‐to‐severe psoriasis patients: 12‐week results from two Phase 3 trials

Guenther, Lyn; Warren, Richard B; Cather, Jennifer; Sofen, Howard; Poulin, Yves; Lebwohl, Mark; Terada, Tadashi; Bleakman, Alison Potts; Zhu, Baojin; Burge, Russel; Reich, Kristian; Kerkhof, Peter van de

doi:10.1111/jdv.14377

Cited by 14 publications

(17 citation statements)

References 35 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 29 Ixekizumab was also shown to significantly improve skin-related relationship and sexual difficulties. 30 Pruritus significantly impacted the QoL of patients with psoriasis. 31 In Uncover-2 and -3, itching severity was measured using an 11-point Numerical Rating Scale (NRS).…”

Section: Improvement In Quality Of Life (Qol)mentioning

confidence: 99%

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis

Sekhon

Jeon

Nakamura

et al. 2017

PTT

View full text Add to dashboard Cite

Psoriasis vulgaris is a chronic, immune-mediated systemic disease that affectŝ7.5 million people in the US. It can be treated with many therapies, often in combination, which include topicals, phototherapy, oral systemics, and biologics. Biologic agents target specific components of the immune system involved in the pathogenesis of psoriasis including TNF-alpha, IL-12, IL-17, and IL-23. The biologic ixekizumab, approved for the treatment of moderate–severe plaque psoriasis in the US, targets IL-17. This review describes the role of IL-17 in psoriasis, the mechanism by which ixekizumab targets this cytokine, and the clinical utility of ixekizumab.

show abstract

Section: Improvement In Quality Of Life (Qol)mentioning

confidence: 99%

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis

Sekhon

Jeon

Nakamura

et al. 2017

PTT

View full text Add to dashboard Cite

show abstract

“…23-30 Several post hoc analyses of these original trials have assessed various outcomes in different subgroups of patients. 31-41 Ixekizumab efficacy has been evaluated retrospectively in patients who had failed treatment with secukinumab 42 and directly compared with ustekinumab in a prospective trial. 43,44…”

Section: Clinical Efficacymentioning

confidence: 99%

“…35,36 Additionally, several subanalyses reported positive patient-reported outcomes, including health-related quality of life and itch severity, skin-related personal relationship difficulties, and facial psoriasis. 37-41 In a separate retrospective analysis of 17 patients with moderate to severe plaque psoriasis who had failed secukinumab treatment, 88.2% (15/17) responded to ixekizumab at 12 weeks. 42…”

Section: Clinical Efficacymentioning

confidence: 99%

Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Further development of biologics involved introduction of other biological drugs, i.e. the monoclonal antibodies that block interleukin 12 and 23 (ustekinumab) or target interleukin 23 (guselkumab, tildrakizumab, risankizumab) as well as those which are capable of blocking interleukin 17 (secukinumab, ixekizumab and brodalumab) [9][10][11]. It is worth noting that tofacitinib, which is one of the synthetic small molecules, plays an important role in the psoriasis treatment [12].…”

Section: Introductionmentioning

confidence: 99%

The effects of selected biologics and a small molecule on Health-Related Quality of Life in adult plaque psoriasis patients: A systematic review and meta-analysis

2020

View full text Add to dashboard Cite

Background The Dermatology Life Quality Index (DLQI) is commonly used to assess the quality of life of patients with skin diseases. Clinical trials confirm the positive effect of the use of biologics and new molecules on the quality of life of patients with plaque psoriasis. Main objectives Investigation of the effect of infliximab, adalimumab, ixekizumab, secukinumab and tofacitinib on Health-Related Quality of Life (HRQOL) measured by the DLQI in adult plaque psoriatic patients with respect to the patients’ race, type of used agent/placebo, agent’s dosage and treatment duration as well as the DLQI score prior to and after commencement of treatment. Material and methods Systematic literature searching for referential papers written in English using four databases: PubMed, EMBASE, Scopus, ClinicalTrials.gov as well as and manual searching (Google) Cochran’s (Q) and I2 tests were used for evaluation of heterogeneity or the degree of variation in the true effect size estimates between the analysed studies. The standardized mean difference (the SMD; Hedge’s g score) was applied to measure the differences between the two means (i.e. two groups: treated vs non-treated or treated vs placebo). The data coding and Hedge's g values were calculated according to the guidance of MetaXL software version 5.3. Main results 43 studies, in total 25,898 individuals, were evaluated by the DLQI and weighted mean scores were derived for the analysis. The mean DLQI scores ranged from 6.83 to 17.8 with the overall DLQI score of 12.12 (95%CI: 11.24 to 13.06). A random-effects model demonstrated significant considerable heterogeneity of the study results (I2 = 98%; p<0.001). Conclusion Infliximab, adalimumab, ixekizumab, secukinumab and tofacitinib in adult plaque psoriatic patients improved HRQOL measured by the DLQI. The patients with lower quality of life before treatment obtained better results.

show abstract

Impact of ixekizumab treatment on skin‐related personal relationship difficulties in moderate‐to‐severe psoriasis patients: 12‐week results from two Phase 3 trials

Abstract: Ixekizumab improves patient-reported skin-related PRD difficulties in patients with moderate-to-severe psoriasis.

Cited by 14 publications

References 35 publications

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis

Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis

The effects of selected biologics and a small molecule on Health-Related Quality of Life in adult plaque psoriasis patients: A systematic review and meta-analysis

Contact Info

Product

Resources

About